Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,598,344
  • Shares Outstanding, K 155,665
  • Annual Sales, $ 233,660 K
  • Annual Income, $ 12,670 K
  • EBIT $ -1 M
  • EBITDA $ 0 M
  • 60-Month Beta 2.19
  • Price/Sales 20.55
  • Price/Cash Flow 352.82
  • Price/Book 24.85

Options Overview Details

View History
  • Implied Volatility 84.62% ( +7.44%)
  • Historical Volatility 79.61%
  • IV Percentile 47%
  • IV Rank 59.83%
  • IV High 134.65% on 01/24/24
  • IV Low 10.10% on 06/10/24
  • Put/Call Vol Ratio 0.43
  • Today's Volume 12,001
  • Volume Avg (30-Day) 10,182
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 147,695
  • Open Int (30-Day) 110,491

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.08
  • Number of Estimates 5
  • High Estimate 0.11
  • Low Estimate 0.06
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +188.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.61 +30.65%
on 10/24/24
36.50 -19.07%
on 11/14/24
+4.97 (+20.23%)
since 10/15/24
3-Month
20.81 +41.95%
on 08/16/24
36.50 -19.07%
on 11/14/24
+8.60 (+41.07%)
since 08/15/24
52-Week
10.98 +169.03%
on 11/16/23
36.50 -19.07%
on 11/14/24
+18.27 (+162.11%)
since 11/15/23

Most Recent Stories

More News
TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics: Q3 Earnings Snapshot

TGTX : 29.54 (-4.23%)
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

TGTX : 29.54 (-4.23%)
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

TGTX : 29.54 (-4.23%)
TG Therapeutics: Q2 Earnings Snapshot

TG Therapeutics: Q2 Earnings Snapshot

TGTX : 29.54 (-4.23%)
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

Our first-ever twin bill.

AAPL : 225.00 (-1.41%)
QCOM : 160.50 (-2.12%)
AMZN : 202.61 (-4.19%)
MNKD : 6.80 (-3.13%)
SNBR : 12.34 (-9.60%)
MANH : 272.62 (-2.55%)
TGTX : 29.54 (-4.23%)
QRVO : 65.61 (-1.04%)
ZM : 81.14 (-1.80%)
WOOF : 4.01 (-4.30%)
VZ : 41.65 (+1.91%)
MCD : 292.63 (-1.99%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

TLSA : 0.8905 (-3.66%)
LLY : 746.20 (-4.93%)
RHHBY : 35.8400 (-0.83%)
BIIB : 159.99 (-2.97%)
TGTX : 29.54 (-4.23%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TLSA : 0.8905 (-3.66%)
LLY : 746.20 (-4.93%)
RHHBY : 35.8400 (-0.83%)
BIIB : 159.99 (-2.97%)
TGTX : 29.54 (-4.23%)
Why TG Therapeutics Stock Was Rocketing Higher This Week

The company raised guidance for sales of its drug for relapsing multiple sclerosis.

TGTX : 29.54 (-4.23%)
TG Therapeutics: Q1 Earnings Snapshot

TG Therapeutics: Q1 Earnings Snapshot

TGTX : 29.54 (-4.23%)
TG Therapeutics: Q4 Earnings Snapshot

TG Therapeutics: Q4 Earnings Snapshot

TGTX : 29.54 (-4.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 33.22
2nd Resistance Point 32.23
1st Resistance Point 30.88
Last Price 29.54
1st Support Level 28.55
2nd Support Level 27.57
3rd Support Level 26.22

See More

52-Week High 36.50
Last Price 29.54
Fibonacci 61.8% 26.75
Fibonacci 50% 23.74
Fibonacci 38.2% 20.73
52-Week Low 10.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar